CXCR4-using HIV-1 was previously shown to replicate more efficiently in a healthy donor-derived CD4 + CD38 + than in a CD4 + CD38 − T-cell subset after stimulation with interleukin (IL)-4. Here, we identified 3 cellular genes, which were expressed to a higher level in an IL-4-stimulated CD38 − subset. One of the 3 genes, RNF125/TRAC-1, was involved in the down-regulation of HIV-1 replication not only in cell lines, but also in peripheral blood mononuclear cells. RNF125/TRAC-1 bears the RING finger domain, important for E3 ubiquitin protein ligase. Mutations in this domain of RNF125/TRAC-1 led to the loss of HIV-1 down-modulatory activity, suggesting that E3 ligase activity is necessary. In addition, the results of Northern blotting and reporter gene analysis indicated that RNF125/TRAC-1 function occurs at the viral transcription step. These results suggest that RNF125/TRAC-1 could function to recruit host factor(s) controlling HIV-1 transcription to the ubiquitin-proteasome pathway.
Introduction
HIV-1 can enter into proliferating and quiescent CD4 + T cells; interestingly resting T cells do not support productive HIV-1 infections (Stevenson et al., 1990; Tang et al., 1995; Zack, 1995) . However, stimulation of T cells from the resting G0 to G1b phase is sufficient to render the cells susceptible to HIV-1 infection and replication (Korin and Zack, 1998) . Exposure of T cells to cytokines, such as interleukin (IL)-2, IL-4, IL-7 or IL-15 that do not trigger cell division could also render them susceptible to HIV-1 replication in the absence of any other stimuli (Unutmaz et al., 1999) . These findings suggest that partial activation of resting T cells is sufficient and mitosis is not necessary for HIV-1 replication.
Some reports suggested that HIV-1 infection leads to a shift from a type 1 (IL-2, interferon-γ) to a type 2 (IL-4, cytokine profile with HIV-1 disease progression (Clerici and Shearer, 1994; Maggi et al., 1994; Meyaard et al., 1994) . For example, the in vitro stimulation of peripheral blood mononuclear cells (PBMCs) derived from HIV-1-infected individuals at early stages of infection preferentially produced type 1 cytokines, whereas that of PBMCs from HIV-1-infected individuals at late stages preferentially produced type 2 cytokines, such as IL-4 (Clerici et al., 1993) . In fact, the increased production of IL-4 in the course of HIV-1 infection has been reported (Klein et al., 1997; Navikas et al., 1994) . Other reports, however, have not been able to document such a type 1 to type 2 cytokine shift with disease progression (Estaquier et al., 1995; Romagnani and Maggi, 1994) . Meanwhile, the chemokine receptors CXCR4 and CCR5 have been identified as the main co-receptors for HIV-1 (Berger et al., 1999) . A predominance of CCR5-using (R5) strains is observed during the early establishment of HIV-1 infection and throughout the asymptomatic period. Subsequently, in a substantial proportion of individuals, a shift to an enrichment of CXCR4-using (X4) strains occurs, concomitant with accelerated CD4 + T-cell depletion (Connor et al., 1997; Penn et al., 1999) . In addition to some reports about increasing type 2 cytokines and the X4 strain, the ratio of CD38 + to CD38 − T-cell subsets has been reported to increase during the course of infection, as described below. Human CD38 is a type II surface glycoprotein expressed on premature hematopoietic cells, but its expression is detectable at low levels on mature cells and again at high levels on activated lymphocytes such as T cells, B cells, dendritic cells and natural killer cells (Malavasi et al., 1994; Savarino et al., 2000) . In HIV-1-infected patients, CD38 is a prognostic marker of HIV-1 progression and high proportions of T cells expressing CD38 could be an indicator of disease progression (Savarino et al., 2000) . In contrast, the decreased proportions of T cells expressing CD38 are a good indicator for the effectiveness of highly active antiretroviral therapy (HAART) (Autran et al., 1997; Vigano et al., 1998) . Thus, CD38 expression on T cells seems to be associated with HIV-1 progression.
We previously reported that X4 HIV-1 replicated more efficiently in a CD4 + CD38 + than in a CD4 + CD38 − T-cell subset derived from healthy donors (Horikoshi et al., 2001) . The different susceptibility of CD38 subsets to X4 HIV-1 was observed after stimulation of the cells with IL-4 (Horikoshi et al., 2002) . The expression levels of CD4 and CXCR4 were not apparently different between these 2 subsets, suggesting that the high susceptibility of the CD38 + subset to X4 HIV-1 was not related with expression levels of the HIV-1 receptor and coreceptor on the cell surface (Horikoshi et al., 2001) . A possible explanation for the different susceptibility of CD38 subsets to X4 HIV-1 is the contribution of host cellular factors to downregulate HIV-1 replication in the CD38 − subset and/or to upregulate HIV-1 replication in the CD38 + subset. In this study, we performed GeneChip analysis to compare expression levels in individual host genes between CD4 + CD38 − and CD4 + CD38 + subsets before and after IL-4 stimulation. Three genes were identified to show higher expressions in the CD38 − subset after IL-4 stimulation. One gene, named RNF125/TRAC-1, was revealed to play an important role to down-modulate HIV-1 replication in primary PBMCs, probably at the transcription step. RNF125/TRAC-1 bears the RING finger domain and has E3 ubiquitin protein ligase activity. Mutations at the RING domain actually affected the down-modulatory activity. Generally, the modification of proteins with ubiquitin chains by this ligase is a prerequisite for their proteasomal degradation (Hershko and Ciechanover, 1998; Pickart, 2001) . Based on our data, we propose the function of RNF125/TRAC-1 for the ubiquitination of unidentified host cellular factor(s) that could be crucially involved in the regulation of HIV-1 replication.
Results
Identification of host cellular genes that are expressed to a higher level in a CD4 + CD38 − than CD4 + CD38 + subset by IL-4 stimulation
We previously reported that an IL-4-stimulated CD4 + CD38
+ subset showed higher susceptibility to X4 HIV-1 than an IL-4-stimulated CD4 + CD38 − subset (Horikoshi et al., 2002; Li et al., 2005) . In addition, this difference between CD38 subsets was shown to be derived from the events after the integration step . In this study, we first confirmed this difference in infection rate between IL-4-stimulated CD38 + and CD38 − subsets with the VSVG/HIV-1 possessing luciferase gene (Fig.  1A) . CD38 subsets in Set 1 and Set 2 experiments were prepared from the resting CD4 + T-cell fraction isolated from healthy donor-derived PBMCs. The subsets were cultured with or without IL-4 for 3 days before infection with VSVG/HIV-1. As expected, in both Set 1 and Set 2 experiments, luciferase activity remained low in IL-4-unstimulated subsets and was at a similar level in both subsets. In contrast, when the CD38 + subset was stimulated with IL-4 followed by infection, luciferase activity was increased approximately 6-and 24-fold in both Set 1 and Set 2 experiments, respectively (Fig. 1A) . One possible explanation for this different susceptibility between CD38 subsets to X4 HIV-1 may be the difference in cellular host factors that could be involved in viral replication. Therefore, we compared expression levels in individual human genes by GeneChip analysis between CD38 + and CD38 − subsets, both of which were unstimulated and stimulated with IL-4 (data not shown). The results showed that 122 cellular genes were up-regulated more than 2-fold in the CD38 + subset by IL-4 stimulation, which corresponded to ∼0.37% of all genes on the GeneChip. In addition, 49 cellular genes were up-regulated more than 2-fold in the CD38 − subset by IL-4 stimulation, which corresponded to ∼ 0.15% of all genes on the GeneChip. Among these genes, the common up-regulated genes in CD38 + and CD38 − subsets were 26 genes, which corresponded to ∼ 21% of all up-regulated genes in CD38 + and to ∼ 53% in CD38 − subset (Fig. 1B) . The other ∼ 79% of upregulated genes in CD38 + and the other ∼ 47% of up-regulated genes in CD38 − subset may be involved in the different susceptibility to HIV-1 between CD38 + and CD38 − subsets. At least, it was suggested that the other ∼ 47% up-regulated genes in CD38
− subset could not up-modulate HIV-1 replication and may function to down-modulate HIV-1 replication. In this study, we focused on down-modulators of HIV-1 replication and performed the additional GeneChip analysis. Among the upregulated genes in CD38 − but not in CD38 + by IL-4 stimulation, only 3 genes (IL-9, M-CSF and RNF125/TRAC-1) showed higher expression levels in IL-4-stimulated CD38
− than in IL-4-stimulated CD38 + subset ( Fig. 1B and Table 1 ). Therefore we further analyzed the 3 genes (IL-9, M-CSF and RNF125/TRAC-1) more in detail.
RT-PCR of 3 genes identified by GeneChip analysis
To confirm the GeneChip data, CD4 + CD38 subsets were similarly prepared and stimulated with IL-4 for 3 days, then subjected to semi-quantitative RT-PCR and quantitative PCR analyses ( Fig. 2A) . The results showed a clear difference in IL-9, M-CSF and RNF125/TRAC-1 between IL-4-stimulated CD38 subsets: 8.2-fold, 3.4-fold and 3.9-fold higher expressions, respectively ( Fig. 2A, lower panel) . Thus, the results of real-time PCR analysis were essentially consistent with those of GeneChip analysis. Since M-CSF and RNF125/TRAC-1 were clearly up-regulated in the IL-4-stimulated CD38 − compared to CD38 + subset and their mRNA levels were relatively high, we focused on these 2 genes. We examined the possible induction of these 2 gene expressions in the CD38 subsets by IL-4 stimulation. The CD4 + CD38 subsets were cultured with and without IL-4 for 3 days and subjected to semi-quantitative RT-PCR and real-time PCR analyses (Fig. 2B) . The result showed that the expressions of M-CSF and RNF125/TRAC-1 were significantly up-regulated by IL-4 stimulation in the CD38 − subset, whereas the up-regulation in the CD38 + subset was only faint. Similar results were obtained in CD38 subsets independently prepared from 2 other healthy donors (data not shown).
Although M-CSF is known to be expressed in various cells, including lymphocytes, and to be induced by IL-4 in T cells (Praloran, 1991; Rettenmier and Sherr, 1989) , the expression of the M-CSF receptor, c-fms, is restricted only to the monocytemacrophage lineage (Datta et al., 1992; Weber et al., 1989) . On the other hand, RNF125/TRAC-1 mRNA was reported to be predominantly expressed in lymphoid tissues, especially T cells (Zhao et al., 2005) . Therefore, we further characterized the latter gene more in detail. The expression level of RNF125/TRAC-1 in PBMCs at the mRNA level was significantly higher than various cell lines including 293T and Jurkat cell lines (data not shown), as previously reported (Zhao et al., 2005) . In addition, Western blotting also showed a high expression of RNF125/ TRAC-1 in CD38 − subset after stimulation with IL-4 (Fig. 2C ).
Down-modulatory effect of RNF125/TRAC-1 on VSVG/HIV-1 replication
To examine the possible contribution of RNF125/TRAC-1 to the down-modulation of HIV-1 replication, we used lentiviral vector in order to transfer this gene into Jurkat T cells, because the lentiviral vector we used is generally believed not to affect the subsequent infection and replication of HIV-1 (Bukovsky et al., 1999) . As a control, a lentiviral vector containing the GFP gene was used. Under the conditions that GFP expression in Jurkat cells was detected more than 90% at 24 h post-transduction, the RNF125/TRAC-1 gene was transduced into the cells by the lentiviral vector. As expected, more than 90% of the cells expressed RNF125/TRAC-1 at 24 h post-transduction by immunofluorescence staining (Fig. 3A , left panel). In addition, the data showed punctate staining pattern. To investigate its subcellular localization more in detail, 293T cells were transfected with RNF125/TRAC-1 expression plasmid. At 24 h posttransfection, RNF125/TRAC-1 protein was found to be localized in a punctate cytoplasmic distribution (data not shown). Next, transduced cells with the RNF125/TRAC-1 or GFP gene were infected with VSVG/HIV-1. At 24 h post-inoculation, cells expressing RNF125/TRAC-1 showed decreased luciferase activity by approximately 50% compared to cells expressing GFP (Fig.  3A , right panel). In addition, the proliferation of cells expressing RNF125/TRAC-1 was not different from that of cells expressing GFP (Fig. 3B ). The trypan blue exclusion also indicated no apparent cell death among cells expressing RNF125/TRAC-1 or GFP (data not shown). Thus, the ectopic expression of RNF125/TRAC-1 was shown to down-modulate HIV-1 replication without host cell damage. Therefore, we next examined the 5 Jurkat T cells were transduced by lentiviral vector containing GFP or RNF125 (RNF125/TRAC-1-FLAG) (30 ng of p24 Gag). At 24 h post-transduction, immunofluorescence staining was performed using anti-FLAG antibody (left panels). At 24 h post-transduction, cells were infected with VSVG/HIV-1 (10 ng of p24 Gag) (right panel). At 24 h post-inoculation, luciferase activity was measured. The relative luciferase activities are shown as a fold increase by comparing them to the activities of GFP-transduced cells. * P b 0.01, for significant difference compared to GFP-transduced cells, determined by Student's paired t-test. Error bars represent standard deviations from 6 independent experiments. (B) Jurkat T cells were transduced by lentiviral vector containing GFP or RNF125 (RNF125/TRAC-1-FLAG) (30 ng of p24 Gag). At 48 h post-transduction, cell proliferation was determined by the cell proliferation assay. Error bars represent standard deviations from 3 independent experiments. Nocodazole, cells treated with nocodazole as a positive control for cell proliferation inhibition. (C) 293T cells were transfected with 100 nM of RNF125 (RNF125/TRAC-1-specific) or GAPDH-specific siRNA, or cells were cotransfected with 100 nM of RNF125 (RNF125/TRAC-1-specific) siRNA and a plasmid expressing RNF125-escape(1). At 48 h post-transfection, RNA was extracted, and semi-quantitative RT-PCR analysis was performed (left panel). The cDNA equivalent to 140 ng of RNA was amplified using gene-specific primers. At 24 h post-transfection, 293T cells were infected with VSVG/HIV-1 (25 ng of p24 Gag) (right panel). At 27 h post-inoculation, luciferase activity was measured. The relative luciferase activities are shown as a fold increase by comparing them to the activities of cells transfected with GAPDH-specific siRNA. Errors bars represent standard deviations of 3 independent experiments. si(1), RNF125/TRAC-1-specific siRNA which targets nucleotides 205 to 225; si(2), RNF125/TRAC-1-specific siRNA which targets nucleotides 525 to 545 of RNF125/TRAC-1 cDNA sequence (GenBank™ Accession Number: NM_017831); RNF125-escape(1), RNF125 (RNF125/TRAC-1-FLAG) expression plasmid containing silent mutations at the recognition site of si(1). effect of the down-regulation of endogenous RNF125/TRAC-1 using siRNA specific to RNF125/TRAC-1. As a control, siRNA to GAPDH was used.
Before HIV-1 infection, we confirmed the silencing effects of these siRNAs to RNF125/TRAC-1. 293T cells were transfected with the siRNA, and the expression level of RNF125/TRAC-1 mRNA was estimated by semi-quantitative RT-PCR analysis (Fig. 3C) . RNF125/TRAC-1-specific [si(1) and si (2)], but not GAPDH-specific siRNA (siGAPDH), significantly decreased the level of RNF125/TRAC-1 mRNA in 293T cells (Fig. 3C, left panel) . As expected, si(1) did not inhibit the expression of a RNF125-escape(1) expression plasmid, which has 5 silent mutations in the target region of the si(1) (Fig. 3C, left panel) . Under these conditions, the 293T cells at 24 h after treatment as above were infected with VSVG/HIV-1. At 24 h post-inoculation, luciferase activity was measured. The cells transfected with RNF125/ TRAC-1-specific siRNAs showed increased luciferase activity compared to siGAPDH-transfected cells: 2.1-and 2.7-fold increases by transfection with si(1) and si(2), respectively (Fig. 3C, right panel) . The increased activity observed after transfection of si(1) was diminished when the 293T cells were transfected with a plasmid expressing RNF125-escape (1) (Fig. 3C, right panel) . These results indicate that RNF125/TRAC-1 has a down-modulatory effect on HIV-1 replication.
Significance of E3 ligase activity of RNF125/TRAC-1 on its down-modulatory effect on HIV-1 replication
The RNF125/TRAC-1 gene encodes a protein of 232 amino acids (aa), containing a RING consensus sequence between aa residues 37 to 75 (Fig. 4A) . The RING finger domain is defined by 8 cysteines and histidines that coordinate 2 zinc ions. The proteins bearing this motif have either a cysteine [C3HC4 RING (RING-HC)] or a histidine [C3H2C3 RING (RING-H2)] in the fifth position (Pickart, 2001) . As determined with consensus sequences, RNF125/TRAC-1 belongs to the RING-HC category. Additionally, the presence of a RING finger domain suggested that RNF125/TRAC-1 could function as an E3 ubiquitin protein ligase. Indeed, an in vitro ubiquitin assay confirmed that RNF125/TRAC-1 is an E3 ligase (data not shown), as previously reported (Zhao et al., 2005) . In order to investigate whether the E3 ligase activity of RNF125/TRAC-1 is necessary to down-modulate HIV-1 replication, we replaced the first cysteine or the first and second cysteines of the RING finger domain with alanine in order to create RNF125/TRAC-1 mutants, C37A and C37/40A, respectively (Fig. 4A) , according to previous papers (Stremlau et al., 2004; Waterman et al., 1999) . In vitro ubiquitin assays confirmed that these 2 mutants dramatically decreased E3 ligase activity (data not shown), and it was consistent with previous paper (Zhao et al., 2005) .
293T cells were cotransfected with an HIV-1 molecular clone (pNL4-3), a plasmid containing GFP gene under the control of the CMV promoter (pCMV-GFP) as a control and the RNF125/ TRAC-1 or the mutant expression plasmid. It was revealed that RNF125/TRAC-1 significantly decreased the release of viral particles in the supernatant in a dose-dependent manner (Fig. 4B,  left panel) . On the other hand, C37A and C37/40A did not decrease the production of viral particles in the supernatant. In this assay, reinfection does not occur, because of the absence of the CD4 receptor on 293T cells. Western blotting revealed a decrease in the HIV-1 gp120 level in cells expressing RNF125/ TRAC-1 (Fig. 4B, right panel, lanes 3 and 4) , suggesting that RNF125/TRAC-1 down-modulated the viral protein synthesis and release of viral particles into the supernatant. In contrast, the expression of RNF125/TRAC-1 did not affect the expression of GFP (Fig. 4B, right panel) . PARP (poly(ADP-ribose) polymerase) was not cleaved in cells transfected with RNF125/TRAC-1 expression plasmid (Fig. 4B, right panel, lanes 3 and 4) , suggesting that the decreased production of viral particles was not due to apoptosis.
Down-modulatory effect of RNF125/TRAC-1 on HIV-1 transcription
To further elucidate the down-modulatory effect of RNF125/ TRAC-1 on HIV-1 replication, 293T cells were cotransfected with the HIV-1 molecular clone together with the RNF125/ TRAC-1 expression plasmid. At 48 h post-transfection, the accumulated viral RNA levels in the cells were compared by Northern blotting (Fig. 5A) . The results showed that RNF125/ TRAC-1 expression induced a significant reduction in all kinds of HIV-1 transcripts including the 9.2 kb unspliced, the 4.3 kb single-spliced and the 2.0 kb double-spliced RNAs in a dosedependent manner (Fig. 5A, lanes 2-4) . In contrast, C37A did not induce such reduction, but rather significantly increased all kinds of viral transcripts (Fig. 5A, lanes 2 and 5) . Furthermore, in order to investigate the effect of RNF125/TRAC-1 on the transcription of integrated HIV-1 LTR promoter, 293T cells stably expressing an HIV-1 LTR-driven luciferase gene (293T-LTR cells) were transfected with the RNF125/TRAC-1 expression plasmid, then luciferase activity was measured at 24 h posttransfection (Fig. 5B, left panel) . RNF125/TRAC-1 was shown to down-modulate the LTR-driven gene expression by approximately 80%. In contrast, when 293T cells stably expressing TK- driven or CMV-driven luciferase gene were transfected with the RNF125/TRAC-1 expression plasmid, RNF125/TRAC-1 downmodulated TK-driven and CMV-driven gene expressions by approximately 10% and 20%, respectively (Fig. 5C ). RNF125/ TRAC-1 did not down-modulate SV40-driven gene expression (Fig. 5C) . Next, we investigated the possible correlation between the down-modulatory effect of RNF125/TRAC-1 on the integrated HIV-1 LTR-driven transcription and the E3 ligase activity of RNF125/TRAC-1. For this, 293T cells were transfected with the C37/40A expression plasmid. The C37/40A mutant did not down-modulate the LTR-driven gene expression (Fig. 5B) . Interestingly, RNF125/TRAC-1 modulated the HIV-1 LTR-driven gene expression in the presence of Tat expression (Fig. 5D) .
Down-modulatory effect of RNF125/TRAC-1 on HIV-1 replication in PBMCs from healthy donors
In order to investigate whether RNF125/TRAC-1 affects HIV-1 replication in primary cells, the RNF125/TRAC-1 gene was transferred into PBMCs using the lentiviral vector. Since the lentiviral vector can not transfer the target gene into resting PBMCs (Maurice et al., 2002) , healthy donor-derived PBMCs were stimulated with PHA, IL-2 or IL-4 for 3 days (Unutmaz et al., 1999) . Using preliminary experiments for the transduction efficiency of lentiviral vector into PBMCs, the best conditions were determined: by the schedule shown in Fig. 6A , the GFPcontaining lentiviral vector was able to express GFP in the PHA-stimulated PBMCs by more than 50% at 4 days postinoculation (data not shown). Under the same conditions, PBMCs were transduced with the RNF125/TRAC-1 gene by the lentiviral vector. At 2 days post-transduction, the cells were infected with VSVG/HIV-1 possessing the luciferase gene. When luciferase activity was measured at 2 days postinoculation with VSVG/HIV-1, it was revealed that at least 6 among 9 PBMCs prepared from different healthy donors showed significant reduction of VSVG/HIV-1 replication by RNF125/TRAC-1 expression, expressed as the relative activity to that of GFP expression (Fig. 6B) . PHA-stimulated PBMCs were similarly transduced with the C37/40A mutant gene by use of a lentiviral vector and then infected with VSVG/HIV-1. The results showed that the expression of the C37/40A rather enhanced VSVG/HIV-1 replication in all 4 PBMCs examined (Fig. 6B) . These results suggest that RNF125/TRAC-1 could be involved in the down-modulation of HIV-1 replication in primary cells.
Discussion
In this paper, we demonstrated that a novel host protein possessing E3 ubiquitin protein ligase activity, RNF125/TRAC-1, could exhibit a down-modulatory effect on HIV-1 replication. The down-modulatory activity of this protein even in the assay using an HIV-1 LTR-driven reporter gene was detected, suggesting its antiviral effect on the viral transcription step.
We had shown that X4 HIV-1 could replicate in the CD4 + CD38 + subset at a higher rate than the CD4 + CD38 − subset after IL-4 stimulation for 3 days (Horikoshi et al., 2002) . In this study, we also found that VSVG/HIV-1 replicated more efficiently in the CD38 + than in the CD38 − subset. We previously showed that there was no apparent difference between both CD38 subsets in their cell proliferation rates before and after IL-4 stimulation , which was consistent with the report that only 5-7% of resting T cells had entered the cell cycle by IL-4 stimulation (Unutmaz et al., 1999) . Thus, the difference in susceptibility of CD38 subsets to HIV-1 might not be associated with cell proliferation. In addition, we also reported that the expression levels of CD4 and CXCR4 were not significantly different between IL-4-unstimulated CD38
− and CD38 + subsets and also between IL-4-stimulated CD38
− and CD38 + subsets, since IL-4 stimulation up-regulated CXCR4 expression on both CD38 subsets at a similar rate (Horikoshi et al., 2002) , suggesting that the receptor and co-receptor expression were not directly correlated with this difference in viral replication between both CD38 subsets. Therefore, we tried to find novel cellular factor(s) that negatively regulate HIV-1 replication in the CD38 − subset and also positively regulate HIV-1 replication in the CD38 + subset after IL-4 stimulation. We compared more than 30,000 cellular genes expressed between IL-4-stimulated CD38 − and CD38 + subsets. Consequently, the results of GeneChip analysis finally prompted us to select the 3 genes, which may down-modulate HIV-1 replication. Following the characterization of 3 individual genes by RT-PCR, the assays of viral replication revealed that one of the genes, RNF125/TRAC-1, exhibited a down-modulatory effect on viral replication, probably at the transcription step.
HIV-1 encodes a transactivator protein Tat, which enhances viral transcription (Bieniasz et al., 1999; Wei et al., 1998) . Therefore, we examined whether RNF125/TRAC-1 modulates transcription in the presence of Tat. By cotransfection of the 293T-LTR cells with Tat and RNF125/TRAC-1 expression plasmids, RNF125/TRAC-1 was shown to down-modulate reporter gene expression in the presence of Tat. However, the effect of RNF125/TRAC-1 was moderate, compared to that in the absence of Tat. One possible explanation may be that Tat partially counteracts the down-regulation effect of RNF125/TRAC-1 on HIV-1 LTR promoter activity. It was reported that Hdm2 binds to Tat and mediates the ubiquitination of the Tat (Bres et al., 2003) . However, our preliminary experiments in 293T cells cotransfected with RNF125/TRAC-1 and Tat expression plasmids followed by immunoprecipitation showed no interaction between Tat and RNF125/TRAC-1 (data not shown). The coexpression of RNF125/TRAC-1 and Tat proteins in 293T cells showed that RNF125/TRAC-1 did not affect the stability of Tat protein. Additionally, the expression of RNF125/TRAC-1 in 293T cells showed that RNF125/TRAC-1 did not affect the stability of cyclin T1 protein, although it was reported that cyclin T1, a mediator of Tat function, is down-regulated by proteasome-mediated proteolysis (Liou et al., 2004) .
Previously, the immunological function of RNF125/TRAC-1 was reported (Zhao et al., 2005) , i.e., positive regulation of T-cell activation as shown by T-cell receptor (TCR)-mediated CD69 up-regulation. Since it is generally believed that the activation state of host cells stimulates HIV-1 replication (Stevenson et al., 1990; Tang et al., 1995; Zack, 1995) , the RNF125/TRAC-1 immunological function may contradict our results in this study; however, there are 2 possible explanations for this discrepancy: (i) The RNF125/TRAC-1 level for the T-cell activation function may be different from that for the modulatory function of HIV-1 replication. Their conclusion of RNF125/TRAC-1 for T-cell activation was derived from evidence that the expression of the carboxyl-terminal truncation of RNF125/TRAC-1 as dominantnegative RNF125/TRAC-1 inhibits TCR-mediated CD69 upregulation in Jurkat T cells. However, they also simultaneously found no more enhancement of TCR-mediated CD69 upregulation in Jurkat cells by the ectopic expression of full-length RNF125/TRAC-1 in addition to the natural level of RNF125/ TRAC-1. In addition, antisense oligonucleotides to RNF125/ TRAC-1 also inhibit the TCR-mediated activation of primary T cells. These results imply that the endogenous level of RNF125/ TRAC-1 might be saturated as a positive regulator of T-cell activation. In contrast, the ectopic expression of RNF125/ TRAC-1 down-modulated HIV-1 replication in Jurkat T cells in this study, suggesting that endogenous RNF125/TRAC-1 is not saturated as a down-modulator of HIV-1 replication. (ii) Another possibility is the different mechanism between RNF125/TRAC-1 functions, T-cell activation and down-modulation of HIV-1 replication. It has been reported that E3 ligase recognizes specific protein substrates (Hershko and Ciechanover, 1998; Pickart, 2001) . Therefore, substrates recognized by RNF125/ TRAC-1 to function as a T-cell activator could be different from those functioning as a down-modulator of HIV-1 replication. In addition, it was reported that RNF125/TRAC-1 catalyzes the formation of Lys 48 -and Lys 63 -linked polyubiquitin chains, indicating that RNF125/TRAC-1 activates degradative and regulatory ubiquitin-dependent pathways, respectively (Zhao et al., 2005) . Thus, RNF125/TRAC-1 may differently regulate these 2 functions by targeting different substrates and also by using degradative and regulatory pathways. It would also be interesting to see whether HIV-1 replication is further decreased by ISG15 (Desai et al., 2006) . A future experiment to be considered would be to delineate Lys 48 (degradation) vs. Lys 63 (regulation) (Badciong and Haas, 2002) in RNF125/TRAC-1 in order to see if there is HIV-1 down-modulation. RNF125/TRAC-1 bears a RING finger domain at aa residues 37 to 75. The in vitro assay revealed that RNF125/TRAC-1 has an E3 ubiquitin protein ligase activity (data not shown), as previously reported (Zhao et al., 2005) . In cells transfected with the HIV-1 molecular clone, C37A and C37/40A did not downmodulate the production of HIV-1 particles but rather enhanced viral production. Northern blotting and reporter gene analysis also showed similar results. One possible explanation is that these mutants function as dominant negatives in our experimental system, although a previous paper (Zhao et al., 2005) did not show the dominant negative effect of theses mutants in T-cell activation. Another possible explanation is that RNF125/TRAC-1's target protein functions to up-regulate HIV-1 replication. Therefore, ectopic expression of RNF125/TRAC-1 might downmodulate the HIV-1 up-regulator(s) and resulted in downmodulation of HIV-1 replication. In contrast, ectopic expression of RNF125/TRAC-1 mutants might not down-modulate the HIV-1 up-regulator(s) and resulted in no down-modulation of HIV-1 replication. These results indicated that the E3 ligase activity of RNF125/TRAC-1 was necessary to down-modulate HIV-1 transcription. It has been reported that the treatment of human cells with a proteasome inhibitor enhanced the efficiency of HIV-1 infection in the early phase (Schwartz et al., 1998) , suggesting that processes involving ubiquitination play important roles in the inhibition of HIV-1 replication. In addition, several studies found that proteasome pathways are involved in the regulation of nuclear factor-κB (Ganesh et al., 2003; Fouchier et al., 1997 ) that affects HIV-1 replication. It is indicated that other E3 ligases, TRIM5α (Stremlau et al., 2004) and POSH (Alroy et al., 2005) , inhibit and enhance HIV-1 replication, respectively. The ubiquitin ligase RNF125/TRAC-1 may present another new role for E3 ligases. Also, a similar RING finger ubiquitin ligase motif has been found on MdmX and is capable of synergistically enhancing Mdm2 ubiquitination (Badciong and Haas, 2002) . Based on our data about the down-modulatory effects of RNF125/TRAC-1 on HIV-1 replication not only in cell lines but also in primary PBMCs, certain unidentified factor(s) controlling HIV-1 transcription could be a target of this protein bearing E3 ubiquitin protein ligase activity in our system. Since RNF125/TRAC-1 had a weak downmodulatory effect on CMV and HSV TK promoter activity, the target protein of RNF125/TRAC-1 may also be slightly involved in controlling CMV and TK transcriptions. Further studies to identify target candidates are needed and this approach could develop a novel therapeutic intervention to suppress viral load in HIV-1-infected individuals.
Materials and methods

Cells
PBMCs of healthy donors were separated on Ficoll-Hypaque gradients. The CD4 + T-cell fraction was isolated from PBMCs by depleting non-CD4 + T cells, as previously described (Horikoshi et al., 2002) . Subsequently, the resting CD4 + T-cell fraction was obtained by depleting CD25 + CD4 + T cells and further separated into 2 T-cell subsets (CD38 + and CD38 − ), as previously described (Horikoshi et al., 2002) . These cells were cultured at 37°C in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (10% FCS-RPMI-1640). 293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FCS. Jurkat T cells were cultured in 10% FCS-RPMI-1640.
Oligonucleotide array analysis
CD4
+ CD38 + and CD4 + CD38 − T-cell subsets were cultured in 10% FCS-RPMI-1640 for 3 days with or without recombinant IL-4 (R&D Systems) at 10 ng/ml, and total RNA was extracted. The activation level of CD4 + CD38 subsets after IL-4 stimulation was examined by phosphorylation of STAT6 by Western blotting. cDNA synthesized from total RNA with the SuperScript Choice System (GIBCO/BRL) was isolated by phenol-chloroform extraction using Phase Lock Gels (Eppen-dorf), followed by ethanol precipitation. The cDNA was used as a template for in vitro transcription to generate biotinylated antisense RNA. The in vitro transcription reaction was performed using an Enzo Bioarray high-yield RNA transcription labeling kit (Affymetrix), according to the manufacturer's instructions. Biotinylated antisense RNA was fragmented and hybridized to the microarrays. The arrays used in this study were the GeneChip® Human Genome U133 Set (Affymetrix). The arrays were washed and stained with streptavidin-R phycoerythrin (Molecular Probes), and then with biotinylated goat antistreptavidin antibody (Sigma). The arrays were stained again with streptavidin-R phycoerythrin. DNA chips were scanned with a confocal laser scanner (Agilent) at a wavelength of 570 nm and data were analyzed with a commercial software package (Microarray Suite 5.0, Affymetrix). IMS 3.0 and Data Mining Tools 3.0 (Affymetrix) were used for data analysis.
Quantitative RT-PCR analyses
CD4
+ CD38 + and CD4 + CD38 − T-cell subsets were stimulated with IL-4 at 10 ng/ml for 3 days, and total RNA was extracted. To synthesize cDNA, 1.5 μg of RNA was reversetranscribed using 200 units of SuperScript II RT (Invitrogen) and 0.5 μg of oligo-dT primer (Invitrogen). The cDNA was used for semi-quantitative PCR and real-time PCR analyses. Semiquantitative PCR conditions were as follows: initial denaturation at 95°C for 2 min, and 25 cycles consisting of 94°C for 30 s, 55°C for 30 s, 72°C for 30 s, and a final elongation step at 72°C for 7 min. Real-time PCR analysis was performed using Platinum SYBR green qPCR SuperMix-UDG (Invitrogen) on an ABI PRISM 7900HT (Applied Biosystems). The conditions were as follows: incubation at 50°C for 30 min, followed by 95°C for 10 min, and 45 cycles consisting of 95°C for 15 s and 60°C for 60 s. Real-time PCR products were also separated on a 1.5% agarose gel to visualize the formation of correct PCR products.
Primers
Primers were purchased from FASMAC (Kanagawa, Japan). The sequences of the primers used for quantitative RT-PCR analysis were 5′-CGTGTGCCTTGAGGTGTTAC-3′ (sense) and 5′-TCGGGTATTAAACGGCAAAG-3′ (antisense) for RNF125/TRAC-1. The sequences of the primers for macrophage colony-stimulating factor (M-CSF), IL-9 and β-actin were previously described (Aharinejad et al., 2004; Oikawa et al., 2004; Yang et al., 2004) . The primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Toyobo Co. Ltd. (Osaka, Japan). Plasmids pNL4-3 (Adachi et al., 1986) was used as an HIV-1 molecular clone. pTat-and pLTR-Luc-containing sequences from pNL4-3 have been previously described . RNF125/ TRAC-1 cDNA for PCR amplification was synthesized using total RNA extracted from IL-4-stimulated CD4 + T cells. PCR amplification was performed with KlenTaq LA DNA polymerase (Sigma), and the primers used were 5′-CTCGA-GATGGGCTCCGTGCTGAGCAC-3′ (CL-1) and 5′-GGATCCTGTGGTGTTCGAGTGATTCA C-3′ (CL-2). The PCR products were cloned into pGEM-T Easy plasmid vector (Promega) and sequenced. pGEM-T Easy/RNF125/TRAC-1 was cleaved with BamHI and XhoI, and ligated to similarly cleaved pEF-BOS (Mizushima and Nagata, 1990) , which permits the addition of a Flag epitope tag at the carboxyl terminus. An RNF125/TRAC-1 mutant, named C37A, was constructed by PCR using pEF-BOS-RNF125/TRAC-1 as a template. Two fragments were first amplified with pfu DNA polymerase (Promega) using sense primer CL-1 together with 5′-GGCA-CACGGCGGCGTCGAAGG-3′ (MU-2) and antisense primer CL-2 together with 5′-CCTTCGACGCCGCCGTGTGCC-3′ (MU-1). These 2 individually amplified fragments were mixed, and then further amplified by PCR with the outside primers CL-1 and CL-2. The resulting fragment containing expected mutations was inserted into the pEF-BOS. Another RNF125/TRAC-1 mutant, named C37/40A, was similarly constructed, except for PCR primers 5′-CTTCGACGCCGCCGTGGCCCTTG-3′ (MU-3) and 5′-CAAGGGCCACGGCGGCGTCGAAC-3′ (MU-4).
Reporter gene analysis
To establish 293T cells stably expressing a reporter gene, 293T cells were cotransfected with pLTR-Luc, a reporter gene driven from herpes simplex virus thymidine kinase promoter (pRL-TK) (Promega), a reporter gene driven from SV40 promoter (pRL-SV40) (Promega) or a reporter gene driven from the cytomegalovirus promoter, together with a puromycin-resistant plasmid. After culturing for 2 days, the cells were further cultured with puromycin for 2 weeks. The established 293T cells were transfected with various plasmids using Lipofectamine 2000 (Invitrogen). Transfection was carried out under the condition to equalize the total DNA amount by adding empty plasmid DNA. Each assay was repeated at least 3 times with cell lysates prepared by independent transfection.
Western blotting
Western blotting was performed as previously described (Kawata et al., 2003) . The antibodies used were specific to FLAG (F7425; Sigma), α-tubulin (T5168; Sigma), poly(ADPribose) polymerase (PARP) (BD Biosciences), HIV-1 gp120 (ViroStat, Portland, ME) and RNF125/TRAC-1 (IMGENEX, Corp., San Diego, CA).
Northern blotting
Northern blotting was performed as previously described (Yamashita et al., 2005) . The [α-32 P]dCTP-labeled probe used was specific to HIV-1 nef. The nef-specific probe was synthesized using the full-length nef gene as a template with the Random Prime Labeling System (Amersham Pharmacia).
Small-interfering (si)RNAs
RNA oligonucleotides against RNF125/TRAC-1 were designed according to the siRNA Target Finder website (http://www.ambion.com/techlib/misc/siRNA_finder.html) and were prepared with a Silencer siRNA Construction Kit (Ambion, Austin, TX) (Kameoka et al., 2004) . The siRNA sequences used were as follows: 5′-AAGTGGACCTGTCCT-TATTGC-3′ for RNF125/TRAC-1 siRNA 1 and 5′-AATACCC-GATGAGAATCCAAG-3′ for RNF125/TRAC-1 siRNA 2. The siRNA directed to GAPDH used as a control in this study was supplied with the Silencer siRNA Construction Kit. The expression plasmid, RNF125-escape(1), contains silent mutations at the siRNA 1 recognition site, in which the wild-type sequence 5′-AAGTGGACCTGTCCTTATTGC-3′ was substituted to 5′-AAATGGACGTGCCCTTACTGT-3′.
Production and infection of vesicular stomatitis virus glycoprotein (VSVG)-pseudotyped recombinant HIV-1 VSVG-pseudotyped recombinant HIV-1, named VSVG/ HIV-1, which expresses the luciferase gene in place of the viral nef gene (Chen et al., 1994; Connor et al., 1995; Fouchier et al., 1997) , was produced in 293T cells, as previously described (Kameoka et al., 2004) . Viral stocks were quantified by HIV-1 Gag p24 antigen-capture enzyme-linked immunosorbent assay (ELISA) (ZeptoMetrix Corporation) (Beauparlant et al., 1996) . VSVG/HIV-1 infection was performed as previously described (Kameoka et al., 2004) . Briefly, 1 × 10 6 CD4 + CD38 subsets cultured with or without IL-4 at 10 ng/ml or PBMCs cultured with phytohemagglutinin (PHA) (Sigma) at 2 μg/ml were exposed to VSVG/HIV-1 (30 ng of p24 Gag) for 1 h at 37°C. After removing the virus, the cells were cultured with recombinant IL-2 at 2 ng/ml (Pepro Tech) for 2 days. For 293T cells, the cells were infected with VSVG/HIV-1 (25 ng of p24 Gag) and cultured for 24 h. Luciferase activity was then measured.
Production and infection by the lentiviral vector
The gene transfer vector pWPT [cPPT-containing selfinactivating (SIN) plasmid under the control of EF-1 promoter] was used to generate pWPT-green fluorescent protein (GFP), pWPT-RNF125/TRAC-1-FLAG, and pWPT-C37/40A-FLAG. Briefly, 293T cells were cotransfected with the gene transfer vector, packaging plasmid (pCMVΔR), and VSVG expression plasmid (pMD2.G). At 2 days post-transfection, infectious lentiviruses were harvested and concentrated by ultracentrifugation at 80,000×g at 4°C for 2 h. PBMCs and Jurkat T cells were adsorbed with the lentiviruses for 1 h and then cultured in the medium.
Immunofluorescence staining
Cells infected with lentiviruses were fixed with 4% paraformaldehyde for 20 min at room temperature. After permeabilization with 0.1% Triton X-100, cells were incubated with anti-FLAG antibody (F7425; Sigma) in Tris-buffered saline (TBS) containing 1% bovine serum albumin. Subsequently, the cells were incubated with Alexa Fluor 488-conjugated goat antirabbit immunoglobulin G (Molecular Probes).
Proliferation assays
Growth studies were performed using the cell proliferation assay kit (Chemicon International) according to the manufacturer's protocol. Briefly, Jurkat T cells infected with lentiviruses were cultured for 48 h. Subsequently, 10 μl of WST-1/ECS solution was added and incubated at 37°C for 4 h. Optical density at 450 nm was then determined using an ELISA reader.
